Other research peptides

Peptides that do not sit in one of the families above.

Peptides that do not sit in one of the families above. A category defined by exclusion is an honest thing for a reference library to have: the alternative is stretching a family definition until it stops meaning anything, which would make every other category on the site less informative.

The entries here have little in common with each other and are best approached individually. What they share is only that each has a published literature worth summarising and no natural home among the receptor families, structural families or model systems that define the rest of the library.

If a compound here later acquires enough company to form a family of its own, it moves. Categories in this library follow the literature rather than the other way round.

Compounds listed below without a link do not yet have a published entry.

Compounds in this category

4 of 4 entries are published. Compounds without a published entry are listed without a link.

  • VIPVIP, vasoactive intestinal peptide, is an endogenous 28-residue peptide of the secretin superfamily and an agonist at the VPAC1 and VPAC2 receptors. The synthetic form is named aviptadil; it is not approved in the United States, and its largest randomised trial was negative.
  • PNC-27PNC-27 is a synthetic chimeric peptide joining a p53-derived HDM-2-binding domain to a cell-penetrating leader sequence. It is reported to lyse cancer cells by binding HDM-2 in their membranes. Its published record is entirely cell-culture and structural work, and it is not approved by the FDA for any indication.
  • SNAP-8SNAP-8 is the trade name for acetyl octapeptide-3, an eight-residue synthetic peptide whose sequence corresponds to a region of the SNARE protein SNAP-25. It is marketed as a cosmetic ingredient, and no indexed study examines the isolated peptide.
  • GlutathioneGlutathione is the endogenous tripeptide gamma-glutamyl-cysteinyl-glycine and the principal intracellular thiol redox buffer. It is not approved by the FDA for any indication; its human trial record by oral and intravenous routes is mixed, and its oral bioavailability has been disputed since 1992.